The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Diet Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Diet Therapy


High impact information on Diet Therapy


Chemical compound and disease context of Diet Therapy


Biological context of Diet Therapy


Anatomical context of Diet Therapy


Associations of Diet Therapy with chemical compounds

  • Intensive diet therapy and self-monitoring of capillary blood glucose were used to obtain postprandial euglycemia; 22% of GDM subjects required insulin [23].
  • The diabetic subjects on diet therapy had relative hyperproinsulinemia, assessed relative to C-peptide concentrations, fasting and in response to hyperglycemic clamping and arginine, compared with control subjects [10].
  • Diet therapy alone was followed by a decrease of 11 mg/100 ml in mean serum cholesterol (p less than 0.01 versus pretreatment value) and no change in serum triglyceride [24].
  • Diabetics controlled on diet therapy showed no change in disaccharidase activity while two diabetics controlled on insulin or insulin-producing drug, glibenclamide, showed a fall in disaccharidase values toward normal [25].
  • RESULTS: The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA1c of 0.69% compared with placebo [26].

Gene context of Diet Therapy

  • To assess the effect of improved metabolic control on PAI-1 activity, nine Type 2 diabetic patients established on diet therapy and with previous stable glycaemic control served as controls [27].
  • MEASUREMENTS: Fasting GH, IGF-I, glucose, insulin and GH secretion after GHRH (100 ug i.v.) were assessed in all patients before and after diet therapy [28].
  • There was no significant difference in serum cholesterol reduction in response to diet therapy between subjects with apoE4 (E4/2, E4/3 and E4/4, n = 12) and without apoE4 (E3/3 and E3/2, n = 40) [29].
  • The University Group Diabetes Program (UGDP) and the U.K. Prospective Diabetes Study (UKPDS) have addressed the issue of insulin versus oral agent or diet therapy in people with recently diagnosed type II diabetes [30].
  • CONCLUSIONS: By increasing postprandial concentrations of the constituent peptides of islet amyloid, sulfonylurea therapy might increase the rate of deposition of islet amyloid and thereby accelerate the decline of % beta in NIDDM, compared with diet therapy alone [31].

Analytical, diagnostic and therapeutic context of Diet Therapy


  1. Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Vasquez, B., Flock, E.V., Savage, P.J., Nagulesparan, M., Bennion, L.J., Baird, H.R., Bennett, P.H. Diabetologia (1984) [Pubmed]
  2. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Kishimoto, M., Yamasaki, Y., Kubota, M., Arai, K., Morishima, T., Kawamori, R., Kamada, T. Diabetes Care (1995) [Pubmed]
  3. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Anderson, J.W., Davidson, M.H., Blonde, L., Brown, W.V., Howard, W.J., Ginsberg, H., Allgood, L.D., Weingand, K.W. Am. J. Clin. Nutr. (2000) [Pubmed]
  4. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Yamanouchi, K., Shinozaki, T., Chikada, K., Nishikawa, T., Ito, K., Shimizu, S., Ozawa, N., Suzuki, Y., Maeno, H., Kato, K. Diabetes Care (1995) [Pubmed]
  5. Validity of urine glucose measurements for estimating plasma glucose concentration. Hayford, J.T., Weydert, J.A., Thompson, R.G. Diabetes Care (1983) [Pubmed]
  6. Change in physician perspective on cholesterol and heart disease. Results from two national surveys. Schucker, B., Wittes, J.T., Cutler, J.A., Bailey, K., Mackintosh, D.R., Gordon, D.J., Haines, C.M., Mattson, M.E., Goor, R.S., Rifkind, B.M. JAMA (1987) [Pubmed]
  7. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Sacks, F.M., Pasternak, R.C., Gibson, C.M., Rosner, B., Stone, P.H. Lancet (1994) [Pubmed]
  8. Diet therapy in rheumatoid arthritis. Kjeldsen-Kragh, J., Haugen, M., Fførre, O. Lancet (1992) [Pubmed]
  9. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Prosser, L.A., Stinnett, A.A., Goldman, P.A., Williams, L.W., Hunink, M.G., Goldman, L., Weinstein, M.C. Ann. Intern. Med. (2000) [Pubmed]
  10. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Rachman, J., Levy, J.C., Barrow, B.A., Manley, S.E., Turner, R.C. Diabetes (1997) [Pubmed]
  11. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Bak, J.F., Møller, N., Schmitz, O., Saaek, A., Pedersen, O. Diabetologia (1992) [Pubmed]
  12. Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy. Norris, C.H. Drugs (1988) [Pubmed]
  13. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Lee, A., Morley, J.E. Obes. Res. (1998) [Pubmed]
  14. Glyburide for the treatment of gestational diabetes. Kremer, C.J., Duff, P. Am. J. Obstet. Gynecol. (2004) [Pubmed]
  15. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. Schade, D.S., Jovanovic, L., Schneider, J. Journal of clinical pharmacology. (1998) [Pubmed]
  16. Apolipoprotein E polymorphism is associated with plasma cholesterol response in a 7-day hospitalization study for metabolic and dietary control in NIDDM. Murakami, K., Shimizu, M., Yamada, N., Ishibashi, S., Shimano, H., Yazaki, Y., Akanuma, Y. Diabetes Care (1993) [Pubmed]
  17. Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch. Li, J., Kaneko, T., Qin, L.Q., Wang, J., Wang, Y., Sato, A. Metab. Clin. Exp. (2003) [Pubmed]
  18. Platelets in treated adrenoleukodystrophy: a brief report. Revell, P., Green, A., Green, S. J. Inherit. Metab. Dis. (1995) [Pubmed]
  19. Anesthetic implications of the child with homocystinuria. Lowe, S., Johnson, D.A., Tobias, J.D. Journal of clinical anesthesia. (1994) [Pubmed]
  20. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Mack, W.J., Selzer, R.H., Hodis, H.N., Erickson, J.K., Liu, C.R., Liu, C.H., Crawford, D.W., Blankenhorn, D.H. Stroke (1993) [Pubmed]
  21. Association of endogenous insulin secretion and mode of therapy with body fat and serum leptin levels in diabetic subjects. Nagasaka, S., Ishikawa, S., Nakamura, T., Kawakami, A., Rokkaku, K., Hayashi, H., Kusaka, I., Higashiyama, M., Saito, T. Metab. Clin. Exp. (1998) [Pubmed]
  22. Improvement of multiple coronary risk factors in obese hypertensives by reduction of intra-abdominal visceral fat. Tochikubo, O., Miyajima, E., Okabe, K., Imai, K., Ishii, M. Japanese heart journal. (1994) [Pubmed]
  23. Obstetric complications with GDM. Effects of maternal weight. Goldman, M., Kitzmiller, J.L., Abrams, B., Cowan, R.M., Laros, R.K. Diabetes (1991) [Pubmed]
  24. Elevation of serum lipid levels during diuretic therapy of hypertension. Ames, R.P., Hill, P. Am. J. Med. (1976) [Pubmed]
  25. Increased disaccharidase activity in human diabetics. Tandon, R.K., Srivastava, L.M., Pandey, S.C. Am. J. Clin. Nutr. (1975) [Pubmed]
  26. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Kelley, D.E., Bidot, P., Freedman, Z., Haag, B., Podlecki, D., Rendell, M., Schimel, D., Weiss, S., Taylor, T., Krol, A., Magner, J. Diabetes Care (1998) [Pubmed]
  27. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Bahru, Y., Kesteven, P., Alberti, K.G., Walker, M. Diabet. Med. (1993) [Pubmed]
  28. Protein intake during aggressive calorie restriction in obesity determines growth hormone response to growth hormone-releasing hormone after weight loss. Megia, A., Herranz, L., Luna, R., Gómez-Candela, C., Pallardo, F., Gonzalez-Gancedo, P. Clin. Endocrinol. (Oxf) (1993) [Pubmed]
  29. Effects of apolipoprotein E phenotype on serum cholesterol level and cholesterol response to diet therapy in patients with hypercholesterolemia. Honda, K., Murase, T. Endocr. J. (1997) [Pubmed]
  30. Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Colwell, J.A. Diabetes (1996) [Pubmed]
  31. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM. Rachman, J., Payne, M.J., Levy, J.C., Barrow, B.A., Holman, R.R., Turner, R.C. Diabetes Care (1998) [Pubmed]
  32. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Anderson, J.W., Allgood, L.D., Lawrence, A., Altringer, L.A., Jerdack, G.R., Hengehold, D.A., Morel, J.G. Am. J. Clin. Nutr. (2000) [Pubmed]
  33. Termination of strict diet therapy in phenylketonuria. A study on EEG sleep patterns and computer spectral analysis. Behbehani, A.W. Neuropediatrics. (1985) [Pubmed]
  34. Lipid lowering: the case for identifying and treating the high-risk patient. Pearson, T.A., Swan, H.J. Cardiology clinics. (1996) [Pubmed]
WikiGenes - Universities